FASLG and neoplasm: Although in vitro/in vivo and preclinical TRAIL-based therapies demonstrated encouraging results and low toxicity owing to tumor-specific activity, the use of death receptors, such as FasL or TNF, as anticancer therapy was soon dampened [205,206,207,208,209,210].